摘要目的:评价伐尼克兰在戒烟门诊实践中的作用。方法:本研究为横断面研究，选取2018年1月至2023年6月在苏州大学附属第一医院呼吸与危重症医学科戒烟门诊就诊、临床资料完整的318例烟草依赖患者为研究对象，所有患者在初诊及后续复诊时接受劝诫、初诊及3个月复诊时监测其呼出气一氧化碳（eCO）浓度，根据是否接受伐尼克兰治疗，分为eCO浓度监测+劝诫组（简称劝诫组，126例）、eCO浓度监测+劝诫+伐尼克兰治疗组（简称伐尼克兰组，192例），随访时间至少3个月，观察戒烟效果，至少连续3个月不吸烟认定为戒烟成功。结果:劝诫组、伐尼克兰组初诊时和3个月复诊时eCO浓度分别为（11.5±4.8）、（11.8±4.3）ppm（ t=0.599， P=0.550）和（7.8±3.6）、（7.3±4.3）ppm（ t=1.181， P=0.239）；两组在3个月随访时的eCO浓度均明显下降（ t=7.293、11.920，均 P<0.001）。劝诫组戒烟成功率显著低于伐尼克兰组（28.6%比40.6%； χ2=4.806， P=0.028）；劝诫组、伐尼克兰组戒烟成功者3个月复诊时eCO浓度均显著低于初诊时［（3.6±2.4）比（15.5±5.6）ppm、（3.5±2.5）比（13.9±5.1）ppm］（ t=17.580、27.180，均 P<0.001）。 结论:在戒烟门诊实践中，伐尼克兰可显著提高戒烟成功率。

abstractsObjective:To explore the effectiveness of varenicline on smoking cessation.Methods:In this cross-sectional study, a total of 318 tobacco-dependent adults with complete medical record were included from January 2018 to June 2023 in the First Affiliated Hospital of Soochow University. All the patients received smoking cessation advices and exhaled carbon monoxide (eCO) detection on initial visit and 3 months later. According to whether they received varenicline, the participants were divided into smoking cessation advices (SCA) group (126 cases) and varenicline (VAR) group (192 cases). The follow-up period was≥3 months. Quit smoking for at least 3 months was regarded as successful smoking-cessation.Results:eCO levels on enrollment and 3 months later for SCA group and VAR group were (11.5±4.8) vs (11.8±4.3) ppm and (7.8±3.6) vs (7.3±4.3) ppm ( P=0.550, 0.239). eCO levels of SCA group and VAR group decreased significantly 3 months later ( t=7.293, 11.920, both P<0.001). Participants in VAR group had significantly higher odds of abstinence than those in SCA group (40.6% vs 28.6%, χ2=4.806, P=0.028). After quit smoking successfully, eCO levels decreased from (15.5±5.6) and (13.9±5.1) ppm to (3.6±2.4) and (3.5±2.5) ppm ( t=17.580, 27.180, both P<0.001) for SCA group and VAR group respectively. Conclusion:Varenicline usage can increase the abstinence rates of tobacco-dependent adults.